the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
August 14, 2018 – The American Food and Drug Administration (FDA) just approved Patisiran (Onpattro) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for …
Patisiran (Onpattro): First targeted RNA-based therapy approved to treat hATTR Read more »
July 22, 2018 – The American Food and Drug Administration (FDA) just approved Ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the IDH1 gene. It is …
Ivosidenib (Tibsovo) for AML-patients with IDH1-mutations Read more »
June 28, 2018 – The American Food and Drug Administration (FDA), a couple of week ago, approved Erenumab-Aooe (Aimovig) for the preventive treatment of migraine in adults. The treatment is given by once-monthly self-injections. Erenumab-Aooe (Aimovig) is the first FDA-approved …
Erenumab-Aooe (Aimovig): Novel preventive treatment for migraine approved Read more »
June 26, 2018 – The American Food and Drug Administration (FDA) just approved Cannabidiol (Epidiolex), for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two rare and severe forms of epilepsy, in patients two years of age …
Epidiolex: Marijuana-derived drug to treat rare forms of epilepsy Read more »
May 05, 2018 – The American Food and Drug Administration (FDA) just approved the combination of Dabrafenib (Tafinlar)/Trametinib (Mekinist) to be administered together for the treatment of anaplastic thyroid cancer (ATC) that cannot be removed by surgery or has …
Dabrafenib/Trametinib-Combo approved for BRAF-positive anaplastic thyroid cancer Read more »
January 29, 2018 – Gastroenteropancreatic neuroendocrine tumors (GEP-NET)s are a rare group of cancers with limited treatment options that affects primarily the pancreas or gastrointestinal tract of patients. The American Food & Drug Administration (FDA) just approved Lutetium (Lu …
December 20, 2017 – The American Food & Drug Administration (FDA) has just approved a novel gene therapy to treat patients with a rare form of inherited vision loss. Voretigene Neparvovec-Rzyl (Luxturna) is the first directly administered gene therapy approved to …
Voretigene Neparvovec-Rzyl (Luxturna): Gene therapy to treat inherited vision loss Read more »
December 16, 2017 – As recent as of December 14, 2017, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the …
X-linked Hypophosphatemia: Burosumab (Crysvita) to the rescue Read more »
November 17, 2017 – The American Food & Drug Administration (FDA) just approved Vestronidase alfa-vjb (Mepsevii), the first treatment for pediatric and adult patients with the inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome. MPS VII …
Treatment for the rare genetic disorder MPS VII approved Read more »
November 16, 2017 – The American Food & Drug Administration (FDA) just approved Ability MyCite, a pill with a sensor that digitally tracks if patients have ingested their medication. This is a very first in its class at the new age …
Abilify MyCite, the first digital pill. Where does all that silicone go? Read more »